Impact of Varying Doses of Prucalopride on Improving Gut Function Recovery After Elective Colorectal Surgery

Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18-75
SponsorFuture University in Egypt

About this trial

Postoperative ileus (POI) is a common complication after abdominal surgery, causing symptoms like nausea, vomiting, abdominal distension, and delayed passage of flatus and stool. Management remains challenging, with limited pharmacological options available. Prucalopride, a selective serotonin 5-HT4 receptor agonist, has shown promise in accelerating gastrointestinal recovery after surgery. However, the optimal timing and dosing for preventing POI remains unclear. Higher doses may provide more potent prokinetic effects in the postoperative setting. his study investigates if higher doses of prucalopride (4 mg) improve bowel function return and hospital stay in elective colorectal surgery patients compared to standard doses and placebo.

Eligibility criteria

Qualifiers

undergoing elective colorectal surgery, including but not limited to colectomy, rectal resection, and sigmoid resection.

Disqualifiers

Emergency surgery

Total colectomy

Creation of a stoma

Pre-existing gastrointestinal disorders

Trial design

Treatments tested in this trial

  • Prucalopride 2mg
  • Prucalopride 4mg
  • Standard Care

Treatment groups

180 Participants
are divided into 3 treatment groups

Sponsors and collaborators